SS Innovations International, Inc.
SSII Nasdaq Surgical & Medical Instruments & Apparatus Financials FY2016βFY2025
What SS Innovations International, Inc. does
No business description yet.
- Legal name
- SS Innovations International, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 10, 2026
- Accession Β· CIK
- 0001213900-26-025440
0001676163
Revenue and margins
SS Innovations International, Inc. had $42.5M of revenue in fiscal 2025, up 105.7% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$22.2M in fiscal 2025, β52.3% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
SS Innovations International, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 9.7%.
Balance sheet
Cash, debt and the ratios that show how comfortably SS Innovations International, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $0.4M | $0.2M | $2.0M | $0.5M | $3.2M |
| Debt incl. finance leases | β | $0.6M | $0.5M | β | β |
| Debt / equity | β | β | 0.0x | β | β |
| Interest coverage | β | β18.3x | β38.7x | β19.5x | β7.4x |
| Current ratio | 1.4x | 0.5x | 2.5x | 1.3x | 1.9x |
| Quick ratio | 1.4x | 0.4x | 1.7x | 0.8x | 1.2x |
| Total assets | $0.4M | $7.0M | $31.5M | $42.4M | $74.2M |
| Total liabilities | β$0.2M | $9.7M | $11.8M | $28.9M | $36.0M |
| Shareholders' equity | $0.6M | β$2.7M | $19.7M | $13.5M | $38.2M |
| Net debt (β = net cash) | β | $0.4M | β$1.5M | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | β / 6 | 4 / 9 | 4 / 8 | 4 / 8 |
| Accruals ratio | β93.5% | β147.3% | β157.8% | β2,131.6% | β459.2% | β300.4% | 75.1% | β28.7% | β26.1% | 11.0% |
| Altman Z'' | β | β | β | β | β | β | β8.29 | β2.41 | β4.94 | β0.09 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | β | β | β | β | β | β | $1.4M | $5.9M | $20.6M | $42.5M |
| Net interest income | β | β | β | β | β | β | $0.0M | $0.2M | $0.3M | $0.5M |
| Gross profit | β | β | β | β | β | β | $0.1M | $0.7M | $8.5M | $19.5M |
| Research and development | $0.1M | $0.1M | $0.0M | $0.1M | $0.0M | $0.0M | $1.0M | $1.1M | $2.5M | $3.7M |
| Operating income | β | β | β | β | β | β | β$3.0M | β$20.3M | β$19.0M | β$8.2M |
| Interest expense | $0.0M | $0.0M | β | $0.0M | $0.0M | β | $0.2M | $0.5M | $1.0M | $1.1M |
| Pretax income | β$0.5M | β$1.0M | β$1.0M | β$3.4M | β$1.1M | β$1.5M | β$3.2M | β$20.9M | β$19.2M | β$8.2M |
| Income tax | β | β | β | β | β | β | β | β | β | $4.0M |
| Net income | β$0.5M | β$1.0M | β$1.0M | β$3.4M | β$1.1M | β$1.5M | β$3.2M | β$20.9M | β$19.2M | β$12.1M |
| Net income to common | β | β | β | β | β | β | β$5.6M | β$20.9M | β | β |
| Diluted EPS | β$0.03 | β$0.05 | β$0.05 | β$0.16 | β$0.05 | β$0.05 | β$0.03 | β$0.14 | β$0.11 | β$0.06 |
| Diluted shares | 0.02B | 0.02B | 0.02B | 0.02B | 0.02B | 0.03B | 0.13B | 0.15B | 0.18B | 0.20B |
| Cash flow | ||||||||||
| Cash from operations | β$0.2M | β$0.4M | β$0.4M | β$0.4M | β$0.1M | β$0.4M | β$6.0M | β$15.4M | β$9.5M | β$18.5M |
| Capital expenditure | β | β | β | β | β | β | $0.2M | $0.5M | $0.7M | $3.7M |
| Free cash flow | β | β | β | β | β | β | β$6.2M | β$15.8M | β$10.2M | β$22.2M |
| Depreciation and amortization | β | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.1M | $0.2M | $0.4M | $1.1M |
| Stock-based compensation | $0.1M | $0.3M | $0.1M | $1.1M | $0.4M | $0.8M | $0.9M | $9.7M | $14.3M | $8.1M |
| Share buybacks | β | β | β | β | β | $0.0M | β | β | β | β |
| Dividends and buybacks | β | β | β | β | β | $0.0M | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $0.2M | $0.5M | $0.0M | $0.0M | $0.2M | $0.4M | $0.2M | $2.0M | $0.5M | $3.2M |
| Total debt | β | β | β | β | β | β | $0.6M | $0.5M | β | β |
| Deposits | β | β | β | β | β | β | β | $5.0M | β | β |
| Current assets | $0.2M | $0.5M | $0.0M | $0.0M | $0.2M | $0.4M | $4.1M | $21.4M | $27.4M | $48.8M |
| Current liabilities | $0.6M | $0.4M | $0.4M | $1.2M | $1.2M | $0.3M | $7.8M | $8.5M | $21.3M | $26.2M |
| Inventory | β | β | β | β | β | β | $0.9M | $7.0M | $10.2M | $17.1M |
| Property and equipment, net | β | $0.0M | $0.0M | $0.1M | $0.0M | $0.0M | $0.4M | $0.7M | $5.4M | $9.1M |
| Intangible assets | $0.0M | $0.0M | $0.0M | β | β | β | β | β | β | β |
| Total assets | $0.3M | $0.5M | $0.1M | $0.1M | $0.3M | $0.4M | $7.0M | $31.5M | $42.4M | $74.2M |
| Total liabilities | $0.6M | $0.4M | $0.4M | $1.2M | $1.2M | β$0.2M | $9.7M | $11.8M | $28.9M | $36.0M |
| Preferred stock | β | β | β | β | β | β | β | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | β$0.4M | $0.1M | β$0.2M | β$1.1M | β$0.9M | $0.6M | β$2.7M | $19.7M | $13.5M | $38.2M |
| Margins | ||||||||||
| Gross margin | β | β | β | β | β | β | 4.2% | 12.3% | 40.9% | 46.0% |
| Operating margin | β | β | β | β | β | β | β206.0% | β345.1% | β91.9% | β19.3% |
| EBITDA margin | β | β | β | β | β | β | β199.3% | β342.5% | β89.8% | β16.8% |
| Net margin | β | β | β | β | β | β | β223.8% | β355.4% | β92.7% | β28.5% |
| FCF margin | β | β | β | β | β | β | β432.8% | β269.2% | β49.2% | β52.3% |
| Net interest share of revenue | β | β | β | β | β | β | 0.2% | 2.6% | 1.6% | 1.2% |
| Returns | ||||||||||
| Return on capital | β | β | β | β | β | β | β | β88.0% | β | β |
| Return on capital employed | β | β | β | β | β | β | 376.6% | β88.0% | β90.1% | β17.1% |
| Return on equity | β | β | β | β | β | β | β | β245.1% | β115.5% | β46.9% |
| Return on assets | β166.0% | β258.7% | β293.0% | β2,436.8% | β499.4% | β397.7% | β86.8% | β108.5% | β51.8% | β20.8% |
| Return on tangible equity | β | β1,801.6% | β | β | β | β253.5% | β | β106.2% | β142.3% | β31.7% |
| Growth | ||||||||||
| Revenue growth | β | β | β | β | β | β | β | 309.1% | 251.5% | 105.7% |
| Share count change | β | 5.6% | 6.8% | 3.2% | 8.5% | 21.9% | 350.0% | 18.7% | 19.2% | 9.7% |
| Financial health | ||||||||||
| Debt / equity | β | β | β | β | β | β | β | 0.0x | β | β |
| Interest coverage | β | β | β | β | β | β | β18.3x | β38.7x | β19.5x | β7.4x |
| Current ratio | 0.4x | 1.1x | 0.1x | 0.0x | 0.1x | 1.4x | 0.5x | 2.5x | 1.3x | 1.9x |
| Quick ratio | 0.4x | 1.1x | 0.1x | 0.0x | 0.1x | 1.4x | 0.4x | 1.7x | 0.8x | 1.2x |
| Capital allocation | ||||||||||
| Capex / revenue | β | β | β | β | β | β | 15.3% | 7.7% | 3.2% | 8.6% |
| Stock comp / revenue | β | β | β | β | β | β | 60.3% | 165.5% | 69.5% | 19.1% |
| Quality scores | ||||||||||
| Piotroski F-score | β | β | β | β | β | β | β | 4.0 | 4.0 | 4.0 |
| Altman Z'' | β | β | β | β | β | β | β8.3 | β2.4 | β4.9 | β0.1 |
| Accruals ratio | β93.5% | β147.3% | β157.8% | β2,131.6% | β459.2% | β300.4% | 75.1% | β28.7% | β26.1% | 11.0% |
Source: SEC EDGAR XBRL filings (CIK 0001676163). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.